Hetero gets WHO prequalification for generic Covid antiviral Paxlovid

This is the first WHO prequalification for Paxlovid - a combination of nirmatrelvir and ritonavir which is recommended for treating mild and moderate Covid patients at the highest risk of hospital admissions, such as unvaccinated, aged, or immunosuppressed patients.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news